Cancer Adoptive Cellular Therapy Network (Can-ACT) for Adult Cancers (UG3/UH3 Clinical Trial Required)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

Deadline: The deadline for this grant has passed

Grant amount: Up to US $6,300,000

Funding uses: Research

Location of project: United States, American Samoa, Guam, Northern Mariana Islands, Puerto Rico, Virgin Islands Show all

Location of residency: United States, American Samoa, Guam, Northern Mariana Islands, Puerto Rico, Virgin Islands Show all

Overview:

NOTE: All applications are due by 5:00 PM local time of applicant organization.

The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting UG3/UH3 applications for the Cancer Adoptive Cellular Therapy (Can-ACT) Network. The goal of this collaborative research network will be to stimulate the conduct of early adoptive cellular therapy clinical trials for adult and pediatric solid tumors. The emphasis is on accelerating the advancement of new cell therapy strategies into clinical testing through novel and collaborative approaches to preclinical testing and translational studies. Can-ACT will support multi-investigator teams with the relevant expertise, assembled to bring new cell therapy products to the clinic.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.